ÐÂÎÅ×ÊѶ
ÆƾÖÌÇÄò²¡Éö²¡£¡£¡£¡£¡£¡£¡£¡£¡aggame¹ÙÍøMCR»·ëÄÁÆ·¨ÁÙ´²Ç°ÁÆЧÏÔÖø
ÈÕÆÚ£º
2026Äê06ÔÂ15ÈÕ 15:43
ÌÇÄò²¡Éö²¡ÊÇʲô £¿£¿£¿£¿£¿£¿£¿
ÌÇÄò²¡Éö²¡£¡£¡£¡£¡£¡£¡£¡£¨diabetic nephropathy£¬£¬£¬£¬ £¬DN£©ÊÇÌÇÄò²¡×îÑÏÖغÍ×î³£¼ûµÄ΢Ѫ¹Ü²¢·¢Ö¢Ö®Ò»£¬£¬£¬£¬ £¬ÔÚҽѧÉÏÒ²³ÆΪÌÇÄò²¡ÉöСÇòÓ²»¯Ö¢¡£¡£¡£¡£¡£¡£¡£¡£ËüÊÇÂýÐÔÉöÔಡ£¡£¡£¡£¡£¡£¡£¡£¨chronic kidney disease£¬£¬£¬£¬ £¬CKD£©ºÍÖÕÄ©ÆÚÉöÔಡ£¡£¡£¡£¡£¡£¡£¡£¨end stage renal disease, ESRD£©µÄÖ÷Òª²¡Òò1¡£¡£¡£¡£¡£¡£¡£¡£ÏÖÔÚ£¬£¬£¬£¬ £¬ÔÚÎÒ¹úÒÔÖÂÈ«ÇòÌÇÄò²¡Éö²¡·¢²¡Âʾù³ÊÉÏÉýÇ÷ÊÆ¡£¡£¡£¡£¡£¡£¡£¡£
ÌÇÄò²¡Éö²¡ÊÇÓÉÓÚºã¾Ã¸ßѪÌÇ״̬µ¼ÖÂÉöÔà½á¹¹ºÍ¹¦Ð§Öð½¥ÊÜËðµÄ²¡ÀíÀú³Ì¡£¡£¡£¡£¡£¡£¡£¡£» £»£»£»£»£»£»£»¼Õß»úÌå±£´æ¼«ÆäÖØ´óµÄ´úлÔÓÂÒ£¬£¬£¬£¬ £¬Ò»µ©Éú³¤µ½ÖÕÄ©½×¶Î£¬£¬£¬£¬ £¬ÍùÍù±ÈÆäËûÉöÔ༲²¡ÖÎÁÆÔ½·¢¼¬ÊÖ¡£¡£¡£¡£¡£¡£¡£¡£ÌÇÄò²¡Éö²¡ÔçÆÚÌØÕ÷ÐԸıä°üÀ¨ÉöСÇòÂ˹ýÂÊÔö¸ß¡¢ÉöÌå»ýÔö´ó£¬£¬£¬£¬ £¬Ëæºó·ºÆð΢Á¿°×ÂÑ°×Äò£¬£¬£¬£¬ £¬¼Ì¶øÉú³¤ÎªÁÙ´²ÂÑ°×Äò¡¢ÉöÏËά»¯£¬£¬£¬£¬ £¬×îÖÕµ¼ÖÂÉö¹¦Ð§¾ÙÐÐÐÔϽµ£¬£¬£¬£¬ £¬Ö±ÖÁÖÕÄ©ÆÚÉöË¥½ß1¡£¡£¡£¡£¡£¡£¡£¡£
£¨Í¼Æ¬ÈªÔ´£ºhttps://www.hjtdsm.com/yiyong/dn£©
¼òÎöÏÖÓÐÁÆ·¨£¬£¬£¬£¬ £¬¿ÉÒÔ·¢Ã÷£¬£¬£¬£¬ £¬È±·¦Äܹ»Ö±½Ó¡¢Ç¿Á¦×è¶ÏÉöÔàÄÚÔÚÑ×Ö¢ºÍÏËά»¯Àú³ÌµÄ¶à°ÐµãÒ©Î£¬£¬£¬ £¬ÊÇÄ¿½ñÌÇÄò²¡Éö²¡ÖÎÁÆÁìÓò×îÖ÷ÒªµÄÁÙ´²Î´Öª×ãÐèÇ󡣡£¡£¡£¡£¡£¡£¡£
aggame¹ÙÍø£¨ÒÔϼò³Æ“aggame¹ÙÍø”£©×ÔÖ÷Ñз¢µÄС·Ö×Ó»·ëÄ£¨MCR¶àëÄ£©ÔÚ×Ô¾õÐÍÌÇÄò²¡Éö²¡Ä£×ÓСÊó——db/dbСÊóÉÏÈ¡µÃÁËÏÔÖøÁÆЧ£¬£¬£¬£¬ £¬Í¨¹ý¶à°ÐµãÐͬÔöЧ£¬£¬£¬£¬ £¬ÓÐÍû´øÀ´DNµÄÁÙ´²ÐÂÑ¡Ôñ£¡
MCR»·ëÄÁÆЧÏÔÖø
db/dbСÊóÊÇÑо¿ÔçÆÚÌÇÄò²¡Éö²¡²¡±äµÄ³£ÓÃÄ£×Ó£¬£¬£¬£¬ £¬ÆäÓÉÓÚ»ùÒòÍ»±äµ¼ÖÂÊÝËØÊÜÌ幦ЧȱÏÝ£¬£¬£¬£¬ £¬³ýÁ˻᷺Æð·ÊÅÖ¡¢¸ßѪÌǵÈÖ¢×´£¬£¬£¬£¬ £¬¸ÃÄ£×ÓСÊóͨ³£» £»£»£»£»£»£»£»¹ÔÚÉúÃüÔçÆÚÌåÏÖ³öÏÔ×ŵÄÉöСÇòËðÉË£¨·Ê´ó¡¢Ï¸°ûÔö¶àºÍÉöСÇòÓ²»¯£©£¬£¬£¬£¬ £¬Ëæ×ÅÄêËêµÄÔöÌí¶ø¼ÓÖØ£¬£¬£¬£¬ £¬»¹ÌåÏÖ³öÖеÈˮƽµÄÂÑ°×Äò¡£¡£¡£¡£¡£¡£¡£¡£
ÊÔÑéЧ¹ûÏÔʾ£¬£¬£¬£¬ £¬¾ÓÉΪÆÚ8ÖܵÄÖÎÁÆ£¬£¬£¬£¬ £¬Óë¿Õȱ±ÈÕÕ×édb/dbСÊóÏà±È£¬£¬£¬£¬ £¬MCR»·ëĸ߼ÁÁ¿×éСÊóµÄÌÇÉöÏà¹ØÖ¸±ê¾ùÓÐÏÔ×ŵĸÄÉÆ£º
1¡¢ ¶àÌǺÍÌÇÂÑ°×ˮƽ£ºÏÔÖø½µµÍ×éÖ¯ÖжàÌǺÍÌÇÂÑ°×ˮƽ£» £»£»£»£»£»£»£»ÓëÄ£×Ó×éÏà±ÈϽµ·ù¶ÈÔ¼2/3£¬£¬£¬£¬ £¬ÓëGLP-1¶àëÄ×éÁÆЧÏ൱£» £»£»£»£»£»£»£»
2¡¢ ½ºÔÂÑ°×ˮƽ£º´ó·ù¶È½µµÍ½ºÔÂÑ°×ˮƽ£¨Ô¼2/3£©£¬£¬£¬£¬ £¬ïÔ̽ºÔ³Á»ý£¬£¬£¬£¬ £¬ÏÔÖø¸ÄÉÆÉöÔàÏËά»¯Ë®Æ½£¬£¬£¬£¬ £¬ÓëGLP-1¶àëÄ×éÁÆЧÏ൱£» £»£»£»£»£»£»£»
3¡¢ ÄòÂÑ°×ˮƽ£ºÖÎÁÆ4Öܽ«ÄòÂÑ°×ˮƽ´Ó»ùÏß½µÖÁÒ»°ë¡£¡£¡£¡£¡£¡£¡£¡£
ͼ1. db/dbСÊóÉöÔಡ±äͼ
G1¿µ½¡±ÈÕÕ×é/G2Ä£×Ó×é/G3»·ëĵͼÁÁ¿×é/ G4»·ëĸ߼ÁÁ¿×é/G5 GLP-1¶àëÄ×é
MCR»·ëÄ£º¶à°ÐµãÐͬÔöЧ
MCR»·ëÄÔÚÌÇÄò²¡Éö²¡ÖÐÌåÏÖ³öµÄ׿ԽÁÆЧ£¬£¬£¬£¬ £¬Ô´ÓÚÆä×÷ΪһÖÖÐͬÐÔË«ÊÜÌ弤¶¯¼ÁµÄÆæÒìÉè¼Æ¡£¡£¡£¡£¡£¡£¡£¡£¸Ã·Ö×ÓʹÓÃÆä¹¹ÏóÔ¼ÊøµÄ»·ëĽṹ£¬£¬£¬£¬ £¬ÊµÏÖÁ˶ԺÚƤÖÊËØÊÜÌåÑÇÐÍMC1RºÍMC4RµÄ¸ßÇ׺ÍÁ¦¼°Ñ¡ÔñÐÔ¹²¼¤»î¡£¡£¡£¡£¡£¡£¡£¡£
ÕâÖÖË«ÖØ°ÐÏò×÷ÓÃÒý·¢ÁËÏÔÖøµÄÐͬÔöЧЧӦ£¬£¬£¬£¬ £¬ÅäÏàÖúÓÃÓÚÌÇÄò²¡Éö²¡µÄ½¹µã²¡Àí»·½Ú£¬£¬£¬£¬ £¬×îÖÕµ¼ÖÂÂÑ°×Äò¼õÇá¡¢×ãϸ°û±£» £»£»£»£»£»£»£»¤¼°ÉöСÇòÂ˹ý¹¦Ð§¸ÄÉƵȶàά¶È²¡ÀíÖ¸±êµÄÏÔÖøÄæת£¬£¬£¬£¬ £¬Õ¹ÏÖÁ˶à°Ðµã¸ÉÔ¤Õ½ÂÔÔÚÖØ´ó´úлÐÔ¼²²¡ÖÎÁÆÖеÄÍ»³öÓÅÊÆ¡£¡£¡£¡£¡£¡£¡£¡£
¼¤»îMC1R£ºÃâÒßµ÷Àí¿¹Ñ×+ÒÖÖÆÏËά»¯Àú³Ì+Ö±½Ó±£» £»£»£»£»£»£»£»¤×ãϸ°û
MC1RÖ÷Òª±£´æÓÚƤ·ôÉ«ËØϸ°û¡¢ÃâÒßϸ°ûºÍÉöÔàϸ°û£¨°üÀ¨×ãϸ°ûºÍϵĤϸ°û£©¡£¡£¡£¡£¡£¡£¡£¡£Í¨¹ý¼¤»îMC1R£¬£¬£¬£¬ £¬ÏÔÖøÒÖÖÆNF-κBµÄ»î»¯£¬£¬£¬£¬ £¬ïÔÌһϵÁдÙÑ×ϸ°ûÒò×Ó£¨TNF-α¡¢IL-6µÈ£©µÄ±¬·¢2 3£» £»£»£»£»£»£»£»Í¬Ê±Ôö½ø¿¹Ñ×Òò×Ó£¨ÈçIL-10£©µÄÊÍ·Å2 3£¬£¬£¬£¬ £¬µ÷ÀíÃâÒßϸ°û£¬£¬£¬£¬ £¬¸ÄÉÆÌåÄÚÑ×֢΢ÇéÐΣ¬£¬£¬£¬ £¬Å¤×ªÉöÔà´ÙÑ×״̬¡£¡£¡£¡£¡£¡£¡£¡£
ÉöÔàÏËά»¯£¨Ó²»¯£©Êǵ¼Ö¹¦Ð§ËðʧµÄ×îºóͨ·¡£¡£¡£¡£¡£¡£¡£¡£ÓÐÑо¿Åú×¢£¬£¬£¬£¬ £¬ºÚƤÖÊËؼ¤¶¯¼Á±»Ö¤Êµ¿ÉÒÔÞ׿¹´ÙÏËά»¯Òò×Ó£¨ÈçTGF-⣩£¬£¬£¬£¬ £¬´Ó¶øïÔ̽ºÔÂÑ°×µÈϸ°ûÍâ»ùÖʵĺϳɣ¬£¬£¬£¬ £¬ÑÓ»ºÉöСÇòÓ²»¯ºÍ¼äÖÊÏËά»¯µÄÀú³Ì4¡£¡£¡£¡£¡£¡£¡£¡£
×ãϸ°ûÊÇ×é³ÉÉöÔàÂ˹ýÆÁÕϵÄÒªº¦Ï¸°û£¬£¬£¬£¬ £¬ÆäËðÉ˺ÍÍÑÂäÊÇÂÑ°×ÄòµÄÖ÷ÒªÔµ¹ÊÔÓÉ¡£¡£¡£¡£¡£¡£¡£¡£Ò»Ð©Ñо¿Ö¸³ö£¬£¬£¬£¬ £¬ºÚƤÖÊËؼ¤¶¯¼ÁÄÜͨ¹ýÖ±½Ó×÷ÓÃÓÚ×ãϸ°ûÉϵÄÊÜÌ壨ÈçMC1R£©£¬£¬£¬£¬ £¬ÎȹÌÆäϸ°û¹Ç¼Ü£¬£¬£¬£¬ £¬ÒÖÖƵòÍö£¬£¬£¬£¬ £¬´Ó¶ø´Ó½á¹¹ÉÏά»¤Â˹ý¹¦Ð§µÄÍêÕûÐÔ£¬£¬£¬£¬ £¬ïÔÌÂÑ°×Äò5 6¡£¡£¡£¡£¡£¡£¡£¡£
ͼ2. MCRÔÚÉöÔàϸ°ûÖеÄÂþÑÜ5
¼¤»îMC4R£º¸ÄÉÆÒȵºËضԿ¹ºÍ´úл
MC4RÖ÷Òª±£´æÓÚÖÐÊàÉñ¾ÏµÍ³£¬£¬£¬£¬ £¬¼ÓÈëµ÷ÀíÄÜÁ¿Æ½ºâºÍʳÓû¡£¡£¡£¡£¡£¡£¡£¡£Í¨¹ý¼¤»îMC4R£¬£¬£¬£¬ £¬¸ÄÉÆÈ«ÉíÒȵºËØÃô¸ÐÐÔºÍÆÏÌÑÌÇ´úл£¬£¬£¬£¬ £¬ÓÐÀûÓÚ´ÓȪԴÉÏÖÎÁÆÌÇÄò²¡Éö²¡——ÌÇÄò²¡¡£¡£¡£¡£¡£¡£¡£¡£
MCR»·ëÄ£º¶à¼²²¡ÁìÓòDZÔÚÓ¦ÓÿÉÄÜÐÔ
Õ¹ÍûδÀ´£¬£¬£¬£¬ £¬aggame¹ÙÍø½«ÒÔMCR»·ëÄÔÚ¼õÖØ´úлÁìÓòÈ¡µÃµÄÍ»ÆÆΪ»ùʯ£¬£¬£¬£¬ £¬ÒÀ¸½Æä×÷ÓûúÖƵĽ¹µãÓÅÊÆ£¬£¬£¬£¬ £¬Æð¾¢ÍØÕ¹ÖÐÊàÉñ¾ÏµÍ³£¨CNS£©¼°×ÔÌåÃâÒߣ¨×ÔÃ⣩µÈDZÁ¦ÖØ´óµÄÐÂ˳Ӧ֢ÁìÓò¡£¡£¡£¡£¡£¡£¡£¡£
Êг¡Ô¶¾°ÓëÕ½ÂԽṹ
È«ÇòÌÇÄò²¡Éö²¡ÖÎÁÆÒ©ÎïÊг¡Õý´¦ÓÚ¿ìËÙÔöÌí½×¶Î£¬£¬£¬£¬ £¬Ô¼30%-40%µÄÌÇÄò²¡»¼Õß»áÉú³¤ÎªÌÇÄò²¡Éö²¡£¡£¡£¡£¡£¡£¡£¡£¬£¬£¬£¬ £¬»¼Õß»ùÊýÖش󡣡£¡£¡£¡£¡£¡£¡£2024ÄêÈ«ÇòDNÒ©ÎïÊг¡¹æÄ£ÒÑÍ»ÆÆ120ÒÚÃÀÔª£¬£¬£¬£¬ £¬Ô¤¼Æ2030Ä꽫Áè¼Ý300ÒÚÃÀÔª£¬£¬£¬£¬ £¬Ä긴ºÏÔöÌíÂÊ´ï12.5%7¡£¡£¡£¡£¡£¡£¡£¡£Öйú×÷ΪȫÇòÌÇÄò²¡»¼Õß×î¶àµÄ¹ú¼Ò£¬£¬£¬£¬ £¬ÕïÁÆÂʵÄÒ»Á¬ÌáÉýʹÆä³ÉΪ×î¾ßÔöÌí»îÁ¦µÄÊг¡Ö®Ò»¡£¡£¡£¡£¡£¡£¡£¡£
Ö»¹ÜÏÖÓбê×¼ÁÆ·¨Ò»Ö±½ø»¯£¬£¬£¬£¬ £¬µ«ÉÐÎÞÄܹ»ÄæתÏËά»¯Àú³ÌµÄÌØÒìÐÔÒ©Îï¡£¡£¡£¡£¡£¡£¡£¡£MCR»·ëÄ´Ó¿¹Ñס¢¿¹ÏËά»¯¡¢´úлµ÷ÀíÈý´ó½¹µã»·½Úͬʱ½éÈ룬£¬£¬£¬ £¬ÓëÏÖÓÐÁÆ·¨ÐγÉÓÅÒ컥²¹£¬£¬£¬£¬ £¬ÓÈÆäÔÚ¿¹ÏËά»¯·½Ãæ¾ß±¸ÆæÒì²î±ð»¯ÓÅÊÆ¡£¡£¡£¡£¡£¡£¡£¡£
ÏÖÔÚ£¬£¬£¬£¬ £¬¹«Ë¾Ñз¢¹ÜÏßÕýÎȲ½Íƽø£¬£¬£¬£¬ £¬ºóÐø½«Öص㿪չϵͳµÄÁÙ´²Ç°Ò©Ð§Ó붾ÀíѧÑо¿£¬£¬£¬£¬ £¬Ïà¹Ø½¹µã»¯ºÏÎïÒÑ»ñµÃרÀûÊÚȨ£¬£¬£¬£¬ £¬¹¹½¨Á˼áʵµÄÊÖÒÕ±ÚÀÝ¡£¡£¡£¡£¡£¡£¡£¡£ÔÚ´ËרÀû¼Ó³ÖÏ£¬£¬£¬£¬ £¬aggame¹ÙÍø½«È«Á¦¼ÓËÙÕâÒ»²î±ð»¯¶àëÄÐÂÒ©µÄÑз¢Àú³Ì£¬£¬£¬£¬ £¬Ö¾ÔÚÔçÈÕ½«ÆäÍÆÏòÁÙ´²£¬£¬£¬£¬ £¬Ô츣ȫÇò»¼Õߣ¬£¬£¬£¬ £¬Í¬Ê±ÇÀÕ¼ÕâǧÒÚÀ¶º£Êг¡µÄÕ½ÂԸߵء£¡£¡£¡£¡£¡£¡£¡£
×ÊÁÏȪԴ
1.Öйú¹«ÖÚ¿µ½¡Íø£¨2014£©£¬£¬£¬£¬ £¬¾ÍÕïÖ¸ÄÏ ³£¼û¼²²¡ ÌÇÄò²¡Éö²¡.http://www.chealth.org.cn/mon/diseases/article/MA144004836.html
2. Wang, W., Guo, D. Y., Lin, Y. J., & Tao, Y. X. (2019). Melanocortin Regulation of Inflammation. Frontiers in endocrinology, 10, 683. https://doi.org/10.3389/fendo.2019.00683
3. Ahmed, T. J., Montero-Melendez, T., Perretti, M., & Pitzalis, C. (2013). Curbing Inflammation through Endogenous Pathways: Focus on Melanocortin Peptides. International journal of inflammation, 2013, 985815. https://doi.org/10.1155/2013/985815
4. ÕŽõ.ºÚƤÖÊËضԾÖÔî½Ú¶ÎÐÔÉöСÇòÓ²»¯Ö¢µÄÖÎÁÆ×÷Óü°»úÖÆÑо¿[D].Ö£ÖÝ´óѧ,2022.DOI:"". http://www.tzsti.com:90/D/Thesis_Y3990408.aspx
5. Chang, M., Chen, B., Shaffner, J., Dworkin, L. D., & Gong, R. (2021). Melanocortin System in Kidney Homeostasis and Disease: Novel Therapeutic Opportunities. Frontiers in physiology, 12, 651236. https://doi.org/10.3389/fphys.2021.651236
6. Luipa Khandker, PhD; Priyanka Dhingra, PhD; John H. Dodd, PhD; Carl Spana, PhD; Paul S. Kayne, PhD. (2023). Melanocortin 1 Receptor (MC1R) Agonist PL8177 Protects Against Podocyte Loss in a Streptozotocin-Induced <br/>Rat Model of Diabetic Nephropathy. 14th Biennial International Podocyte Conference Philadelphia, PA. 2023. https://palatin.com/wp-content/uploads/2023/05/PAL-G23PL8.3015-IPD-2023-Khandker-PL8177-Protects-Against-Podocyte-Loss-Poster-0518-2-OK-TO-PRINT.pdf
7. 2025ÖÁ2030ÌÇÄò²¡Éö²¡ÐÐÒµÔËӪ̬ÊÆÓëͶ×ÊÔ¶¾°ÊÓ²ìÑо¿±¨¸æ.https://max.book118.com/html/2025/1022/8123135105010001.shtm
Ïà¹ØÍƼö
ÍøÕ¾½¨É裺ÖÐÆó¶¯Á¦ ̨ÖÝ